We build and capture value from company formation to expansion stage to public market investing
We have built significant domain knowledge, network and experience in several key areas; and we continue to follow the science and expand our team aligned to these trends.
We have built or played a significant role in cell and gene therapy companies and continue to look at new modalities that push the boundaries of science.
We focus on disruptive and minimally invasive surgical instruments, imaging equipment, new biological materials, high-value consumables and other innovative solutions. We also have portfolio companies delivering special diagnostic testing, IVD, bedside diagnostics and genetic testing both from the product and services side.
We continue to believe there is room for new entrants to provide high quality services to patients, research communities and hospitals. We focus on R&D services and big data companies with advanced high entry barrier processes and innovative business models.